{
    "clinical_study": {
        "@rank": "43778", 
        "brief_summary": {
            "textblock": "RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy\n      using triptorelin may fight prostate cancer by reducing the production of androgens.\n\n      PURPOSE: Randomized phase III trial to compare the effectiveness of long-term hormone\n      therapy and triptorelin with no further treatment in treating patients who have advanced\n      prostate cancer previously treated with radiation therapy and 6 months of androgen\n      suppression."
        }, 
        "brief_title": "Hormone Therapy in Treating Patients With Advanced Prostate Cancer", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the best hormonal scheme to be associated with pelvic radiotherapy in the\n           curative management of prostatic carcinoma for hormonal treatment with regards to\n           treatment outcome (overall survival, clinical disease free survival, local regional\n           control), quality of life (treatment side effects, sexual function), and health economy\n           (cost effectiveness ratio).\n\n      OUTLINE: This is a randomized, multicenter study.\n\n      Patients receive external radiation for 5 weeks, followed by a pelvic boost given for 2\n      weeks and a 6 month combined androgen blockage initiated at the onset of external\n      irradiation. Flutamide (Eulexin) or bicalutamide (Casodex) may be used as the antiandrogens.\n      Antiandrogen treatment starts 1 week before the first injection of triptorelin.\n\n      Patients are then randomized to one of two treatment arms.\n\n        -  Arm I: Patients receive no further treatment.\n\n        -  Arm II: Patients receive antiandrogen for 2.5 years plus and LHRH analogue\n           (triptorelin) administered every 3 months. Patients then continue the LHRH analogue\n           alone for an additional 2.5 years in the absence of disease progression.\n\n      Patients are followed every 6 months for 5 years and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 966 patients will be accrued over 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed adenocarcinoma of the prostate\n\n               -  T1c-T2a-b, N1-2 or pN1-2 (after pelvic lymphadenectomy)\n\n               -  T2c-T4, N0-2\n\n          -  Prior external radiotherapy for locally advanced prostatic carcinoma required\n\n          -  Prior hormone therapy (6 months of combined androgen blockade) for locally advanced\n             prostatic carcinoma required with PSA no greater than 150 ng/mL before administration\n\n          -  No progressive disease after the 6 months of combined androgen blockage\n\n          -  No stages T1c/T2a-b with a negative pelvic lymph nodes status that is assessed\n             clinically or surgically\n\n          -  No lymph node involvement to common iliac and/or periaortic lymph nodes (M1a)\n\n          -  No external iliac lymph node metastasis more than 5 cm in greatest dimension (N3)\n\n          -  No distant metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Any age\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  At least 5 years\n\n        Hematopoietic:\n\n          -  Hemoglobin at least 10 g/dL\n\n          -  WBC at least 2,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No prior or concurrent cancers other than basal cell skin cancer\n\n          -  No serious nonmalignant disease resulting in a life expectancy of less than 5 years\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  No prior biologic therapy for prostate cancer\n\n        Chemotherapy\n\n          -  No prior chemotherapy for prostate cancer\n\n        Endocrine therapy\n\n          -  See Disease Characteristics\n\n        Radiotherapy\n\n          -  See Disease Characteristics\n\n        Surgery\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "966", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003026", 
            "org_study_id": "EORTC-22961", 
            "secondary_id": [
                "EORTC-22961", 
                "EORTC-GU-22961"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "bicalutamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "flutamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "triptorelin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Flutamide", 
                "Triptorelin", 
                "Bicalutamide"
            ]
        }, 
        "keyword": "adenocarcinoma of the prostate", 
        "lastchanged_date": "June 29, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-22961"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "Academisch Ziekenhuis der Vrije Universiteit Brussel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels (Bruxelles)", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "B-2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium", 
                        "zip": "B-9000"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hasselt", 
                        "country": "Belgium", 
                        "zip": "3500"
                    }, 
                    "name": "Virga Jesse Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }, 
                    "name": "Rambam Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guardamangia", 
                        "country": "Malta", 
                        "zip": "MSD 07"
                    }, 
                    "name": "St. Luke's Hospital and Medical School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Hertogenbosch", 
                        "country": "Netherlands", 
                        "zip": "5200 ME"
                    }, 
                    "name": "Groot Ziekengasthuis 's-Hertogenbosch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1091 HA"
                    }, 
                    "name": "Onze Lieve Vrouwe Gasthuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9700 RB"
                    }, 
                    "name": "Academisch Ziekenhuis Groningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6202 AZ"
                    }, 
                    "name": "Academisch Ziekenhuis Maastricht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tilburg", 
                        "country": "Netherlands", 
                        "zip": "5022 GC"
                    }, 
                    "name": "St. Elisabeth Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Obninsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Medical Radiological Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "81190"
                    }, 
                    "name": "Marmara University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stoke-On-Trent", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "ST4 6QG"
                    }, 
                    "name": "City General Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Israel", 
                "Malta", 
                "Netherlands", 
                "Russian Federation", 
                "Turkey", 
                "United Kingdom"
            ]
        }, 
        "official_title": "Long Term Adjuvant Hormonal Treatment With LHRH Analogue Versus No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Months Combined Androgen Blockade - A Phase III Study", 
        "overall_official": [
            {
                "affiliation": "CHU de Grenoble - Hopital de la Tronche", 
                "last_name": "Michel Bolla, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "T. M. de Reijke, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "19516032", 
                "citation": "Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pi\u00e9rart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 Jun 11;360(24):2516-27."
            }, 
            {
                "citation": "Bolla M, van Tienhoven G, de Reijke TM, et al.: Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--results of the randomized EORTC phase III trial 22961. [Abstract] J Clin Oncol 25 (Suppl 18): A-5014, 238s, 2007."
            }, 
            {
                "citation": "Giraud JY, Dusserre A, Conil M, et al.: Results of the dummy-run of EORTC trial no.22961: a phase III study of long term hormonal treatment on locally advanced prostatic carcinoma treated by radiation therapy and a 6 months CAB. [Abstract] Int J Radiat Oncol Biol Phys 51(3 suppl 1): A-699, 378, 2001."
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 1997", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }, 
    "geocoordinates": {
        "Academisch Medisch Centrum": "52.37 4.895", 
        "Academisch Ziekenhuis Groningen": "53.219 6.567", 
        "Academisch Ziekenhuis Maastricht": "50.851 5.691", 
        "Academisch Ziekenhuis der Vrije Universiteit Brussel": "50.85 4.352", 
        "City General Hospital": "53.003 -2.179", 
        "Groot Ziekengasthuis 's-Hertogenbosch": "51.698 5.317", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Marmara University Hospital": "41.005 28.977", 
        "Medical Radiological Research Center": "55.093 36.611", 
        "Onze Lieve Vrouwe Gasthuis": "52.37 4.895", 
        "Rambam Medical Center": "32.83 34.974", 
        "St. Elisabeth Ziekenhuis": "51.586 5.079", 
        "St. Luke's Hospital and Medical School": "35.937496 14.375416", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438", 
        "Universitair Ziekenhuis Gent": "51.053 3.73", 
        "Virga Jesse Hospital": "50.931 5.332"
    }
}